Bayer AG Q3 2010 Investor Handout

2,040 views

Published on

Disclaimer
This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Published in: Investor Relations
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
2,040
On SlideShare
0
From Embeds
0
Number of Embeds
215
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Bayer AG Q3 2010 Investor Handout

  1. 1. Q3 2010 Investor Conference Call • Marijn Dekk Science For A Better Life Q3 2010 Results Investor Conference Call October 28 2010 Marijn Dekkers, CEO
  2. 2. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 2 Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
  3. 3. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 3 Financial performance mainly driven by business expansion at MaterialScience Emerging markets contributed 37% to group sales and continued strong business momentum Xarelto – Rocket AF data presentation expected at upcoming AHA conference €1.6bn lower net debt in the quarter Full year 2010 group outlook reiterated Third Quarter 2010 – Bayer Lifts Sales And Earnings Again
  4. 4. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 4 3rd Quarter 2010 – Bayer Lifts Sales And Earnings Again 8,581 7,392 Sales in € million % portfolio & currency adj. Q3´09 Q3´10 +8% EBITDA pre-special items in € million Q3´09 Q3´10 1,656 1,499 +10% Core EPS in € Q3´09 Q3´10 0.950.78 +22%
  5. 5. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 5 Latin America Eastern Europe Africa & Middle East Emerging Economies Emerging Markets Drive Growth And Contribute Significantly to Group Sales Emerging Economies¹ +17% Others² -1% USA +3% Emerging Asia³ 8% 37% 35% 20% Western Europe +6% Group sales by region Group €8,581m; +8% ~1,300 +23% ~1,100 +12% ~400 +23% ~400 +7% ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia minus Japan, Australia, New Zealand In € million, Δ% yoy Fx adjusted
  6. 6. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 6 -1.6 Cash Flow And Net Debt Development Q3´10 Cash Flow Net Debt Development GCF oFCF 879 Invest- ments 395 In € billion Q2´10 Q3´10 10.7 9.1 1,160 Δ % y-o-y -25% +6% NCF cont. 1,555 +3% In € million -6%
  7. 7. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 7 HealthCare – Challenged US Pharma Business, Ex-US Pharma Sales up 5% Q3´10 Sales Earnings Consumer Health +11% (+3%) Pharma +7% (0%) 1,539 2,732 HealthCare € 4,271m; +9% (+1%) In € million, Δ% y-o-y, ( ) Fx & portfolio adj. 376 Q3´10 765 368 731 -4% -2% 1,099 -4% 1,141 475 311 300 462 -3% -4% 762 -3%786 Q3´10Q3´09 Underlying EBITDA Underlying EBIT Q3´09Price -1% Vol. 2% Fx 8% Portf. 0%
  8. 8. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 8 Expected Newsflow From Key Pharma Pipeline Assets 2010 2011 Expected or upcoming major news flow: Data AHA 2010eROCKET AF phase III trial in stroke prevention in A´fib patients Q4 2010eVEGF Trap-Eye: First data from the VIEW phase III program in wet AMD Q4 2010eFirst filings in DVT treatment and in stroke prevention in A´fib patients Data expected early 2011MAGELLAN trial in VTE prevention in medically ill patients Completion summer 2011eEINSTEIN-PE Data expected 1H 2011VEGF Trap-Eye: Phase III program in CRVO Beyond 2011Riociguat: Phase III in PAH and CTEPH A´fib = atrial fibrillation Completion summer 2011eATLAS TIMI 51
  9. 9. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 9 -16 CropScience – Solid Quarter, Q4 Outlook Projects Higher Adjusted Sales Q3´10 Sales Earnings BioScience +69% (+53%) 1,130 CropScience € 1,341m; +18% (+8%) 86 Crop Protection +16% (+7%) Environmental Science +8% (-3.5%) 125 118 142 +20% 126 +17% 108 -10 -16 Underlying EBITDA Underlying EBIT Q3´10Q3´09 12 33 +175% -4 +75% -28 -37 Q3´10Q3´09 -60% -32% Price 0% Vol. 9% Fx 9% Portf. 0% In € million, Δ% y-o-y, ( ) Fx & portfolio adj.
  10. 10. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 10 Price 10% Vol. 13% Fx 8% Portf. 0% Underlying EBITDA Q3´10Q3´09 409 Q3´10Q3´09 Underlying EBIT 238 260 100 MaterialScience – Q3 Sales on, uEBITDA Above Target, FY Financial Guidance Raised Q3´10 Sales Poly- carbonates +38% (+29%) Polyurethanes +31% (+23%) 726 Earnings MaterialScience € 2,665m; +31% (+23%) CAS* +24% (+18%) 475 Industrial Operations +21% (+17.5%) 143 1.321 * Coatings, Adhesives and Specialties +72% +160% In € million, Δ% y-o-y, ( ) Fx & portfolio adj.
  11. 11. Q3 2010 Investor Conference Call • Marijn Dekkers • Page 11 Full Year 2010 Group Outlook Projects Strong Growth Over 2009 2009 Δ 2010E Q3 Update Sales €31.2bn -6% >5% confirmed uEBITDA €6.5bn -7% >€7bn confirmed Core EPS €3.64 -13% >15% confirmed Sales Fx and portfolio adjusted Outlook depends on planning assumptions as detailed in the 2009 annual report
  12. 12. Q3 2010 Investor Conference Call • Marijn Dekk Science For A Better Life

×